Sarcopenia impairs prognosis of patients with liver cirrhosis

Hanai, Taizo; Shiraki, Makoto; Nishimura, Kayoko; Ohnishi, Sachiyo; Imai, Kenji; Suetsugu, Atsushi; Koji, Takehiko; Shimizu, Masahito; Moriwaki, Hisataka

doi:10.1016/j.nut.2014.07.005

Cited by 334 publications

(383 citation statements)

References 39 publications

Supporting

Mentioning

361

Contrasting

Unclassified

Order By: Relevance

“…This result indicated that these malnutritional factors were important for the survival of patients with HCC treated with sorafenib. Several recent reports indicated that decreased skeletal muscle mass was an important prognostic factor in patients with chronic liver disease and HCC (2,3,5,6). These results suggested that preventing reductions in skeletal muscle thickness may improve the OS of patients treated with sorafenib.…”

Section: Discussionmentioning

confidence: 91%

“…These results suggested that preventing reductions in skeletal muscle thickness may improve the OS of patients treated with sorafenib. The usefulness of nutritional support, such as branched-chain amino acids (BCAA), and exercise therapies to prevent the decrease in skeletal muscle mass were reported (3,15,16). Only in patients with cirrhosis, supplementation with BCAA prevented skeletal muscle loss (BCAA vs. without BCAA, 0.64±1.04 vs. 1.56±1.77, respectively; P=0.10; data not shown).…”

Section: Discussionmentioning

confidence: 99%

“…Sarcopenia is defined as the loss of skeletal muscle mass and muscle dysfunction, and is caused not only by aging, but also by chronic diseases, including liver disease (1)(2)(3). The Japan Society of Hepatology set the sarcopenia assessment criteria in liver disease (4).…”

Section: Introductionmentioning

confidence: 99%

“…These criteria include measuring grip strength and muscle mass by computed tomography (CT) or bioelectrical impairment analysis (BIA). Recently, an increasing number of studies have demonstrated that sarcopenia may affect the clinical state of patients with liver disease (1)(2)(3). Moreover, skeletal muscle wasting assessed by CT has been reported to be a prognostic marker for patients with hepatocellular carcinoma (HCC) treated with sorafenib (5,6).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib

Yamashima

Miyaaki

Honda

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Sarcopenia has been reported to be associated with the prognosis of patients with liver cirrhosis and hepatocellular carcinoma (HCC). The aim of the present study was to determine whether sarcopenia was associated with the prognosis of patients with HCC treated with sorafenib. A total of 40 patients with HCC who were treated with sorafenib were evaluated. As an indicator of skeletal muscle mass, transverse psoas muscle thickness (TPMT) was measured on computed tomography images at the level of the umbilicus prior to treatment initiation and after 1-3 months of treatment. Pre-TPMT/height was not associated with progression-free survival (PFS) or overall survival (OS). The change in TPMT/height prior to and following treatment was also not associated with PFS; however, the change of TPMT/height was an independent factor affecting OS (P=0.020). A total of 40 patients were divided into two groups depending on the degree of TPMT/height loss (mild and severe muscle atrophy groups). Patients with mild muscle atrophy exhibited a significantly longer OS compared with patients with severe muscle atrophy (P=0.045). Thus, the change in skeletal muscle thickness calculated as TPMT/height may be a simple predictor of survival for patients with HCC treated with sorafenib.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib

Yamashima

Miyaaki

Honda

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…It has become widely recognized in the hepatology field because of the significant influence of MML on patients with liver disease. MML is a poor prognostic factor in cirrhosis or hepatocellular carcinoma (HCC) patients [8,9], and a predictor of the development of complications [10,11] and outcomes after surgical treatment [12].…”

Section: Introductionmentioning

confidence: 99%

Constraining Effect of Mild Portal Hypertension against the Negative Influence of Muscle Mass Loss in Cirrhosis after Esophageal Variceal Eradication

Kobayashi¹,

Maruyama²,

Kiyono³

et al. 2017

Clinical-Investigation

View full text Add to dashboard Cite

Background: To elucidate the role of muscle mass loss (MML) in the long-term outcome of cirrhosis after the endoscopic eradication of esophageal varices (EV). Methods and findings:This is a subgroup analysis of 82 prospectively enrolled cirrhosis patients with eradicated EV. A severe portal hypertension (PH) was defined by post-treatment hepatic venous pressure gradient ≥12 mmHg. MML was assessed by skeletal muscle index at the L3 lesion (cm 2 /m 2 ) with the cut-off values of 38 for women and 42 for men (median observation period, 37.4 months). Twenty-four patients (29.3%) had MML. Multivariate analysis showed that a presence of hepatocellular carcinoma (P<0.0001) and a presence of MML (P=0.002) were significant prognostic factors. In the cohort with severe PH, the survival rate was significantly lower in patients with MML than in those without. However, in the cohort without severe PH, the survival rate showed no difference between patients with MML (100% at 1year, 50% at 3 years and 5 years) and those without (92.3% at 1 year and 3 years, 71.8% at 5 years; P=0.278). Conclusions:MML is an independent prognostic factor after the eradication of EV in cirrhosis, and the mild PH exerts a constraining effect against the negative influence of MML.

show abstract